Amarin Corporation plc

Amarin is committed to improving the lives of patients suffering from diseases of the central nervous system. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs. Amarin has a late-stage drug development pipeline. Miraxion, Amarin's lead development compound, is in phase III development for Huntington's disease ("HD"), phase II development for depressive disorders and entering phase IIa development for Parkinson's disease. Amarin's core development pipeline also includes the global rights to an oral forumlation of apomorphine for treating patients with advanced Parkinson's disease and a nasal formulation of lorazepam for treating emergency ( www.amarincorp.com )